Recrutamento encerrado
FASE
Número Europeu 2020-002964-29
IMMU-123-13 TROPiCS-04
A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04)
Detalhes
Destaques